文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

南非耐药结核患者贝达喹啉和氯法齐明血浆清除率个体间差异的药物遗传学研究

Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa.
PubMed 文献 · J Infect Dis · 2022-01-01

该研究在南非耐药结核患者中探讨药物遗传多态性对贝达喹啉、其M2代谢物及氯法齐明血浆清除率个体间差异的影响。在140例可评估遗传关联的参与者中,CYP3A5*3(rs776746)与贝达喹啉清除减慢相关(P=0.0017),杂合子和纯合子分别与清除率减慢15%和30%相关,但与M2无关(P=0.25)。氯法齐明清除率与VKORC1 rs9923231的P值为0.13;全基因组分析中RFX4 rs76345012和CNTN5 rs75285763分别与贝达喹啉和氯法齐明清除率相关,但作者认为可能仅由偶然所致。

要点

  • CYP3A5*3与贝达喹啉清除减慢相关,杂合子和纯合子分别减慢15%和30%。
  • CYP3A5*3与M2代谢物清除率无显著关联(P=0.25)。
  • 氯法齐明清除率与VKORC1 rs9923231关联未达显著(P=0.13)。

核心结论

  • 在南非耐药结核患者中,CYP3A5*3与贝达喹啉清除减慢相关。
  • 不同人群中CYP3A5*3频率的差异可能有助于解释非洲人群中贝达喹啉清除更快的报道。
  • 与RFX4和CNTN5的关联可能仅由偶然所致。

研究设计与样本

  • 研究纳入南非耐药结核患者队列,共195例参与者,其中140例可评估遗传关联。
  • 采用非线性混合效应模型估算血浆清除率。
  • 使用线性回归模型检验药物遗传多态性、全基因组多态性与清除率变异之间的关联。

主要发现

  • 在基于既往全基因组显著关联选取的21个多态性中,rs776746(CYP3A5*3)与贝达喹啉清除减慢相关(P=0.0017),但与M2代谢物清除无关(P=0.25)。
  • CYP3A5*3杂合子和纯合子分别与贝达喹啉清除率减慢15%和30%相关。
  • 氯法齐明清除率的最低P值见于VKORC1 rs9923231(P=0.13)。
  • 全基因组分析中,贝达喹啉和氯法齐明清除率的最低P值分别见于RFX4 rs76345012(P=6.4×10^-7)和CNTN5 rs75285763(P=2.9×10^-8)。

局限性

  • 与RFX4和CNTN5的关联可能仅由偶然所致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma bedaquiline clearance is reportedly more rapid with African ancestry. Our objective was to determine whether genetic polymorphisms explained between-individual variability in plasma clearance of bedaquiline, its M2 metabolite, and clofazimine in a cohort of patients treated for drug-resistant tuberculosis in South Africa. METHODS: Plasma clearance was estimated with nonlinear mixed-effects modeling. Associations between pharmacogenetic polymorphisms, genome-wide polymorphisms, and variability in clearance were examined using linear regression models. RESULTS: Of 195 cohort participants, 140 were evaluable for genetic associations. Among 21 polymorphisms selected based on prior genome-wide significant associations with any drug, rs776746 (CYP3A5∗3) was associated with slower clearance of bedaquiline (P = .0017) but not M2 (P = .25). CYP3A5∗3 heterozygosity and homozygosity were associated with 15% and 30% slower bedaquiline clearance, respectively. The lowest P value for clofazimine clearance was with VKORC1 rs9923231 (P = .13). In genome-wide analyses, the lowest P values for clearance of bedaquiline and clofazimine were with RFX4 rs76345012 (P = 6.4 × 10-7) and CNTN5 rs75285763 (P = 2.9 × 10-8), respectively. CONCLUSIONS: Among South Africans treated for drug-resistant tuberculosis, CYP3A5∗3 was associated with slower bedaquiline clearance. Different CYP3A5∗3 frequencies among populations may help explain the more rapid bedaquiline clearance reported in Africans. Associations with RFX4 and CNTN5 are likely by chance alone.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Haas DW, Abdelwahab MT, van Beek SW, et al. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. J Infect Dis. 2022. PMID: 35091749. doi:10.1093/infdis/jiac024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。